Synthekine Secures $100M Series C Financing
Summary
MENLO PARK, CA, Synthekine Inc., an engineered cytokine therapeutics company, announced the closing of a $100 million Series C financing. Synthekine Inc., an engineered cytokine therapeutics company, announced the closing of a $100 million Series C financing led by The Column Group, with participation from both new and existing investors. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.